Stellate Ganglion Block to Treat Long COVID 19 Case Series

Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05812209

Enrollment

Registered

2023-04-13

Start date

2022-09-01

Completion date

2022-12-31

Last updated

2023-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anosmia, Brain Fog, Cough, Dizziness, Dysautonomia, Dysgeusia, Fatigue Post Viral, Long COVID, Long Covid19, Menstrual Cycle Abnormal, Muscle Pain, Pain, Post Acute COVID-19 Syndrome, Post-COVID-19 Syndrome, Shortness of Breath

Brief summary

An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.

Detailed description

We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.

Interventions

PROCEDUREStellate Ganglion Block

Ultrasound guided block of the Stellate Ganglion with local anesthetics.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

People who scheduled themselves for a SGB in our clinics in Colorado. \-

Exclusion criteria

Stellate Ganglion Block Contraindications \-

Design outcomes

Primary

Measure	Time frame	Description
Symptom Response	3 months	Evaluation of the symptoms response to the Stellate Ganglion Block

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026